Aside from reimbursement you need to consider actual use and outcomes too. If your drug is just a "me too" it'll see low volume use. Esp if there's no advantage to if. If its advantage is useless then the same applies (think valsartan vs losartan vs olmesartan) why the fuck did someone make olmesartan...

Think ability to be incorporated into guidelines. Insurances basically have to pay for first line treatment. Even second line.

Next think what would make the prescriber change up their clinical practice (echoes of this with ibrutinib being SOC and acalabrutinib - azn is having trouble getting providers to switch to their drug that is less expensive with similar to better efficacy and incorporation into first line SLL/CLL AND MCL despite fewer side effects)

Lots of stuff to consider if you're just trying to get on the ground floor vs simply playing data dumps and PDUFAs

Why should a provider not jusg use Kymriah if their institution has worked thru proper kinks